Vysis introduces fluorescence in situ hybridisation (FISH) probes for blood cancers
This article was originally published in Clinica
Vysis has introduced six fluorescence in situ hybridisation (FISH) probes for haematological cancers. The DNA probes have not been cleared by the FDA for clinical use. Vysis and Oncor are awaiting the findings of a US Federal District Court on the patent status of FISH probes.